FI3117216T3 - Menetelmä kiinteäkasvaimisen syövän tunnistamiseksi - Google Patents
Menetelmä kiinteäkasvaimisen syövän tunnistamiseksi Download PDFInfo
- Publication number
- FI3117216T3 FI3117216T3 FIEP15716168.8T FI15716168T FI3117216T3 FI 3117216 T3 FI3117216 T3 FI 3117216T3 FI 15716168 T FI15716168 T FI 15716168T FI 3117216 T3 FI3117216 T3 FI 3117216T3
- Authority
- FI
- Finland
- Prior art keywords
- solid tumor
- psa
- time point
- tumor cancer
- biomarker
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57565—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen [CEA]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1450274 | 2014-03-11 | ||
| SE1450420 | 2014-04-04 | ||
| PCT/SE2015/050272 WO2015137870A1 (en) | 2014-03-11 | 2015-03-11 | Method for detecting a solid tumor cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3117216T3 true FI3117216T3 (fi) | 2023-04-27 |
Family
ID=52829276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP15716168.8T FI3117216T3 (fi) | 2014-03-11 | 2015-03-11 | Menetelmä kiinteäkasvaimisen syövän tunnistamiseksi |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10451626B2 (enExample) |
| EP (2) | EP4220170A3 (enExample) |
| JP (1) | JP6625061B2 (enExample) |
| AU (2) | AU2015230017B2 (enExample) |
| CA (2) | CA2940445C (enExample) |
| DK (1) | DK3117216T3 (enExample) |
| FI (1) | FI3117216T3 (enExample) |
| RU (1) | RU2720148C9 (enExample) |
| WO (1) | WO2015137870A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6308954B2 (ja) | 2012-03-05 | 2018-04-11 | オサケユキテュア・アークティック・パートナーズ・アクチボラゲットＯｙ Ａｒｃｔｉｃ Ｐａｒｔｎｅｒｓ Ａｂ | 前立腺癌のリスク及び前立腺容積を予測する方法及び装置 |
| CN114740202A (zh) | 2014-03-28 | 2022-07-12 | 欧普科诊断有限责任公司 | 与前列腺癌的诊断有关的组合物和方法 |
| US12326453B2 (en) | 2014-03-28 | 2025-06-10 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| EP3253800B1 (en) | 2015-03-27 | 2021-03-03 | Opko Diagnostics, LLC | Prostate antigen standards and uses thereof |
| CA2982262A1 (en) | 2015-04-29 | 2016-11-03 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| US11479878B2 (en) | 2016-03-16 | 2022-10-25 | Dana-Farber Cancer Institute, Inc. | Methods for genome characterization |
| EP3270163B1 (en) * | 2016-07-15 | 2018-09-05 | ProteoMediX AG | Method of detecting proteins in human samples and uses of such methods |
| US20190345565A1 (en) * | 2017-02-01 | 2019-11-14 | Phadia Ab | Method for indicating a presence or non-presence of prostate cancer in individuals with particular characteristics |
| WO2018144678A1 (en) * | 2017-02-03 | 2018-08-09 | The Johns Hopkins University | Mini-cancers utilization for personalized cancer drug regimens |
| RU2664706C2 (ru) * | 2017-06-02 | 2018-08-21 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) | Способ прогнозирования клинического статуса рака предстательной железы |
| JP7127422B2 (ja) * | 2017-08-30 | 2022-08-30 | 東ソー株式会社 | 癌を検出する方法及び検出試薬 |
| WO2020205204A1 (en) * | 2019-04-03 | 2020-10-08 | Opko Diagnostics, Llc | Methods for the detection of prostate cancer |
| IT202000029948A1 (it) * | 2020-12-04 | 2022-06-04 | Nib Biotec S R L | Metodo per la diagnosi di tumore alla prostata in pazienti in differente fascia di età |
| KR20250107193A (ko) * | 2022-10-27 | 2025-07-11 | 마이옴, 인크. | 다수의 데이터 소스들을 조합하여 질병들의 조기 검출을 하기 위한 접근법 |
| WO2024092136A2 (en) * | 2022-10-28 | 2024-05-02 | Memorial Sloan-Kettering Cancer Center | Machine learning modeling for inpatient prediction |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030219840A1 (en) | 2002-05-24 | 2003-11-27 | Mikolajczyk Stephen D. | Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection |
| US20050277137A1 (en) | 2003-08-15 | 2005-12-15 | University Of Pittsburgh | Diagnostic multimarker serological profiling |
| KR100830811B1 (ko) | 2006-09-18 | 2008-05-20 | 충북대학교 산학협력단 | 종양표시인자 검출용 바이오센서 |
| FR2934698B1 (fr) | 2008-08-01 | 2011-11-18 | Commissariat Energie Atomique | Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede. |
| CA2750062A1 (en) | 2009-01-19 | 2010-07-22 | Katrin Stedronsky | Diagnostic assays for prostate cancer using psp94 and psa biomarkers |
| US20120121618A1 (en) | 2009-02-12 | 2012-05-17 | Dana-Farber Cancer Institute, Inc. | Predicting And Treating Prostate Cancer |
| EP2407555A1 (en) * | 2010-07-14 | 2012-01-18 | Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Fundació Privada | Methods and kits for the diagnosis of prostate cancer |
| EP2611943B1 (en) | 2010-09-03 | 2017-01-04 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with prostate cancer risk |
| US20120202888A1 (en) | 2010-10-08 | 2012-08-09 | The Brigham And Women's Hospital, Inc. | Biomarkers of prostate cancer and predicting mortality |
| US20120150032A1 (en) | 2010-12-13 | 2012-06-14 | Julius Gudmundsson | Sequence Variants Associated with Prostate Specific Antigen Levels |
| AU2011352167A1 (en) * | 2010-12-28 | 2013-07-11 | Caris Mpi, Inc. | Molecular profiling for cancer |
| CA2799163C (en) | 2011-12-18 | 2025-01-07 | 20/20 Genesystems, Inc. | Methods and algorithms for aiding in the detection of cancer |
| EP2850432A2 (en) * | 2012-05-16 | 2015-03-25 | Phadia AB | Method for indicating the presence or non-presence of prostate cancer |
| RU2669809C2 (ru) * | 2012-11-20 | 2018-10-16 | Пхадиа Аб | Способ прогноза для индивидуумов с раком предстательной железы |
| MY182773A (en) | 2012-11-20 | 2021-02-05 | Phadia Ab | Method for indicating a presence or non-presence of aggressive prostate cancer |
-
2015
- 2015-03-11 CA CA2940445A patent/CA2940445C/en active Active
- 2015-03-11 JP JP2016556777A patent/JP6625061B2/ja not_active Expired - Fee Related
- 2015-03-11 CA CA3134289A patent/CA3134289A1/en active Pending
- 2015-03-11 RU RU2016139491A patent/RU2720148C9/ru active
- 2015-03-11 AU AU2015230017A patent/AU2015230017B2/en active Active
- 2015-03-11 FI FIEP15716168.8T patent/FI3117216T3/fi active
- 2015-03-11 WO PCT/SE2015/050272 patent/WO2015137870A1/en not_active Ceased
- 2015-03-11 DK DK15716168.8T patent/DK3117216T3/da active
- 2015-03-11 EP EP23150294.9A patent/EP4220170A3/en active Pending
- 2015-03-11 EP EP15716168.8A patent/EP3117216B1/en active Active
- 2015-03-11 US US15/124,769 patent/US10451626B2/en active Active
-
2021
- 2021-09-15 AU AU2021232712A patent/AU2021232712B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015230017A1 (en) | 2016-09-08 |
| RU2720148C9 (ru) | 2020-09-28 |
| JP6625061B2 (ja) | 2019-12-25 |
| RU2016139491A (ru) | 2018-04-16 |
| EP4220170A3 (en) | 2023-12-13 |
| EP3117216B1 (en) | 2023-01-11 |
| CA2940445C (en) | 2021-11-30 |
| US10451626B2 (en) | 2019-10-22 |
| DK3117216T3 (da) | 2023-04-03 |
| EP3117216A1 (en) | 2017-01-18 |
| AU2021232712A1 (en) | 2021-10-14 |
| AU2021232712B2 (en) | 2024-10-03 |
| US20170108501A1 (en) | 2017-04-20 |
| CA2940445A1 (en) | 2015-09-17 |
| RU2016139491A3 (enExample) | 2018-10-15 |
| RU2720148C2 (ru) | 2020-04-24 |
| EP4220170A2 (en) | 2023-08-02 |
| JP2017508970A (ja) | 2017-03-30 |
| AU2015230017B2 (en) | 2021-06-17 |
| CA3134289A1 (en) | 2015-09-17 |
| WO2015137870A1 (en) | 2015-09-17 |
| HK1231559A1 (en) | 2017-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Biomarkers for prostate cancer: from diagnosis to treatment | |
| Bhawal et al. | Challenges and opportunities in clinical applications of blood-based proteomics in cancer | |
| Ferrari et al. | Towards novel non-invasive colorectal cancer screening methods: a comprehensive review | |
| JP2017508970A5 (enExample) | ||
| AU2021232712B2 (en) | Method for detecting a solid tumor cancer | |
| Jaworski et al. | Circulating cell-free tumour DNA for early detection of pancreatic cancer | |
| Spans et al. | The genomic landscape of prostate cancer | |
| Kulbe et al. | Discovery and validation of novel biomarkers for detection of epithelial ovarian cancer | |
| Keup et al. | Combinatorial power of cfDNA, CTCs and EVs in oncology | |
| JP2016508026A5 (enExample) | ||
| MX2018011725A (es) | Metodo para emplear expresion genica para determinar pronostico de cancer de prostata. | |
| CN110249223A (zh) | 血液细胞分析方法及血液细胞分析仪 | |
| Hachem et al. | Contemporary update on clinical and experimental prostate cancer biomarkers: a multi-omics-focused approach to detection and risk stratification | |
| Grizzi et al. | Circulating tumor DNA in gastric adenocarcinoma: future clinical applications and perspectives | |
| Adinew et al. | The prognostic and therapeutic implications of the chemoresistance gene BIRC5 in triple-negative breast cancer | |
| Verma et al. | Biomarkers in prostate cancer epidemiology | |
| Wang et al. | Automatic detection of the circulating cell-free methylated DNA pattern of GCM2, ITPRIPL1 and CCDC181 for detection of early breast cancer and surgical treatment response | |
| JP2016521979A5 (enExample) | ||
| Ravegnini et al. | Simultaneous analysis of SEPT9 promoter methylation status, micronuclei frequency, and folate-related gene polymorphisms: The potential for a novel blood-based colorectal cancer biomarker | |
| Meehan et al. | Tissue-and liquid-based biomarkers in prostate cancer precision medicine | |
| Gao et al. | Proteomic tissue-based classifier for early prediction of prostate cancer progression | |
| Jang et al. | Proteomics of primary uveal melanoma: insights into metastasis and protein biomarkers | |
| Panettieri et al. | Emerging prognostic markers in patients undergoing liver resection for hepatocellular carcinoma: a narrative review | |
| Wu et al. | Identification and validation of the lncRNA MYOSLID as a regulating factor of necroptosis and immune cell infiltration in colorectal cancer following necroptosis-related LncRNA model establishment | |
| Marzec et al. | The transcriptomic landscape of prostate cancer development and progression: an integrative analysis |